Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin Therapy for Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\>= 18 years)~* Aneurysmal subarachnoid hemorrhage~Exclusion Criteria:~* Uncontrolled systemic hypertension (systolic blood pressure \> 220 mmHg)~* Erythrocytosis vera~* Concurrent erythropoietin therapy~* Negative angiography~* Subarachnoid hemorrhage more than 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient

Based on this trial design, predict the completion outcome and termination type (if applicable).